☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
IgA Nephropathy
Travere Therapeutics’ Filspari (sparsentan) Receives the US FDA’s Full Approval for Treating IgA Nephropathy
September 6, 2024
Novartis Reports the US FDA’s Accelerated Approval of Fabhalta to Treat Primary IgA Nephropathy (IgAN)
August 9, 2024
Novartis Highlights Results from the P-III (ALIGN) Study of Atrasentan for the Treatment of IgA Nephropathy (IgAN) at ERA 2024
May 27, 2024
For an Aggregate of $1.8B, Biogen Acquires Human Immunology Biosciences to Strengthen its Immunology Portfolio
May 23, 2024
CSL Vifor and Travere Therapeutics’ FILSPARI (sparsentan) Received European Commission Approval Against IgA Nephropathy
April 24, 2024
Novartis Reports Data from the P-III Study of Fabhalta (iptacopan) for the Treatment of IgA Nephropathy (IgAN)
April 16, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.